Advertisement
UK markets closed

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • CRUDE OIL

    78.82
    +0.34 (+0.43%)
     

  • GOLD FUTURES

    2,323.10
    -8.10 (-0.35%)
     

  • DOW

    38,881.60
    +29.33 (+0.08%)
     

  • Bitcoin GBP

    50,700.74
    +143.93 (+0.28%)
     

  • CMC Crypto 200

    1,316.50
    -48.62 (-3.56%)
     

  • NASDAQ Composite

    16,374.50
    +25.25 (+0.15%)
     

  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Roche skin cancer drugs "too expensive", says UK cost agency

Reuters - UK Focus

LONDON, June 16 (Reuters) - Roche's two-drug combination of Cotellic and Zelboraf for melanoma was rejected by Britain's healthcare cost agency NICE (Milan: NICE.MI - news) as "too expensive" on Thursday, in contrast to the green light given in April to a rival cocktail from Novartis (LSE: 0QLR.L - news) .

Both treatments are designed for people with advanced disease who have a particular genetic profile, known as BRAF V600 mutation-positive melanoma.

The National Institute for Health and Care Excellence (NICE) said Roche's combination offered life-extending benefits but compared to alternatives it cost too much.

The list prices of the two drugs in Britain are 4,275.67 pounds ($6,022) and 7,000 respectively for 28 days, although Roche would have offered a discount for Zelboraf.

ADVERTISEMENT

By comparison, the list price of Novartis' Mekinist and Tafinlar combined is 10,080 pounds, and Novartis also offered a discount.

The size of discounts offered to NICE are commercially confidential.

($1 = 0.7100 pounds) (Reporting by Ben Hirschler; Editing by Mark Potter)